Literature DB >> 17006264

Can renal leukemic infiltration cause hypertension in children?

Seref Olgar1, Sevgi Yetgin, Mualla Cetin, Tulin Aras.   

Abstract

Out of 334 children with acute lymphoblastic leukemia who were treated with St Jude Total XI and Total XIII chemotherapy protocols were investigated and 21 (6.3%) were hypertensive. The incidence of tumor lysis syndrome was higher in the hypertensive group than in the nonhypertensive group (28.6% vs. 11.5%) (P = 0.035). There were no differences between patients treated with high-dose methylprednisolone and prednisolone St Jude Total XI and Total XIII, St Jude Total XIII LR and St Jude Total XIII HR groups in respect of the above-mentioned parameters. Central nervous system involvement, skeletal system involvement, abdominal lymphadenopathy, elevated lactate dehydrogenase and leukocyte count, French-American-British types and immunophenotypes were not found to be statistically significant to the development of hypertension (P > 0.05). We found that renal leukemic infiltration is a risk factor in hypertension development (P = 0.04) and hypertension is a risk factor for renal parenchymal disorder in the follow-up period (P = 0.0001). Six patients presenting with hypertension in the first week of disease therapy were evaluated for renal parenchymal disorder and glomerular filtration rate abnormality in the follow-up period. Glomerular filtration rate abnormality was found in 1 and renal scintigraphic dimercaptosuccinic acid abnormalities (reduced uptake and dilated hypoactivity) were found in 4 patients. Hypertension was also found to be a risk factor for renal parenchymal disorder in the follow-up period.

Entities:  

Mesh:

Year:  2006        PMID: 17006264     DOI: 10.1097/01.mph.0000212990.64435.b9

Source DB:  PubMed          Journal:  J Pediatr Hematol Oncol        ISSN: 1077-4114            Impact factor:   1.289


  8 in total

1.  Refractory arterial hypertension and renal failure combined with cerebral seizures and pancytopenia in a 5-year-old girl with bilateral nephromegaly: Answers.

Authors:  Patrick Hundsdoerfer; Uwe Querfeld
Journal:  Pediatr Nephrol       Date:  2015-08-11       Impact factor: 3.714

2.  A case of persistent hypertension in a 6-year-old: Answers.

Authors:  Mugdha Rairikar; Elizabeth Anyaegbu Onugha
Journal:  Pediatr Nephrol       Date:  2022-09-29       Impact factor: 3.651

3.  Tumor lysis syndrome as a risk factor for posterior reversible encephalopathy syndrome in children with hematological malignancies.

Authors:  Daisuke Suzuki; Ryoji Kobayashi; Akihiro Iguchi; Hirozumi Sano; Kenji Kishimoto; Kazue Yasuda; Kunihiko Kobayashi
Journal:  Int J Hematol       Date:  2014-09-13       Impact factor: 2.490

4.  High blood pressure and hypertension in children with newly diagnosed acute leukemia and lymphoma.

Authors:  Chrystal U Louis; Lavjay Butani
Journal:  Pediatr Nephrol       Date:  2008-01-26       Impact factor: 3.714

5.  Uncontrolled hypertension secondary to leukemic cell infiltration of kidneys in a hemodialysis patient.

Authors:  Kultigin Turkmen; Lutfullah Altintepe; Ibrahim Guney; Ismet Aydogdu; Osman Koc; Mehmet Ali Erkut; Halil Zeki Tonbul
Journal:  Int J Nephrol Renovasc Dis       Date:  2010-06-04

6.  Hemodynamic and biochemical alterations in dogs with lymphoma after induction of chemotherapy.

Authors:  D M Fine; K Selting; R C Backus; N F Rossi; M W Harmon; H E Durham; A W Spier
Journal:  J Vet Intern Med       Date:  2014-03-21       Impact factor: 3.333

Review 7.  Hypertension in Pediatric Acute Lymphoblastic Leukemia Patients: Prevalence, Impact, and Management Strategies.

Authors:  Lindsey Murphy; Kelly Maloney; Lia Gore; Eliza Blanchette
Journal:  Integr Blood Press Control       Date:  2022-01-19

8.  Supportive methods for childhood acute lymphoblastic leukemia then and now: A compilation for clinical practice.

Authors:  Alexandra Podpeskar; Roman Crazzolara; Gabriele Kropshofer; Petra Obexer; Evelyn Rabensteiner; Miriam Michel; Christina Salvador
Journal:  Front Pediatr       Date:  2022-09-12       Impact factor: 3.569

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.